AXIS Capital Holdings heads into its July 28 Q2 earnings with a notable disconnect: options traders are their most bullish in over a year, even as short sellers quietly rebuilt positions through June.
The options signal is the clearest standout this week. The put/call ratio has collapsed to 0.12, more than a full standard deviation below its 20-day average of 0.24 — and close to its 52-week low of 0.07. That means call volume is running at roughly nine times put volume, a degree of bullish skew that looks unusual even for a stock up 6.6% on the week and 15.9% over the past month. The move in options follows a sustained unwind of bearish positioning: the PCR sat above 0.45 as recently as early June, and the compression since then has been sharp and consistent. Whether that reflects genuine conviction or a squeeze of laggard shorts covering into strength is worth watching.
Short interest tells a more cautious supporting story. Bears trimmed exposure nearly 10% over the past week to 2.6% of the free float — still low in absolute terms, but notable given that the same metric jumped 34% over the prior month as the stock dipped. The lending market offers no friction for new shorts: availability is exceptionally loose at 6,485%, meaning more than 72 million shares remain available to borrow against a short position of roughly two million. Borrow costs are barely above zero at 0.38%, near the low end of the past 30-day range. Positioning looks comfortable rather than crowded.
The Street moved constructively on AXS this week. UBS raised its target from $129 to $131 while holding Buy, and Keefe, Bruyette & Woods lifted from $126 to $131, maintaining Outperform — both actions coming today, July 8, ahead of the Q2 print. The consensus mean target is $123.55, which sits about 8% above the current $114.53 close; the stock has now run through several earlier targets set in April's more cautious mood. Bears on the Street flag deteriorating core loss ratios in 2026/27, slowing premium growth in casualty and professional liability, and unfavorable comparisons from the mild 2025 hurricane season. Bulls counter with a structurally improved ROE in the mid-teens, a de-risked balance sheet, and high-single-digit gross written premium growth in 2024 that could accelerate if reinsurance pricing re-hardens. Valuation is undemanding at 7.7x trailing earnings and 1.16x book — the P/E has expanded roughly 0.4 points over the past 30 days as the stock re-rated, but room remains relative to peers.
The institutional ownership picture is orderly rather than crowded at the top. AQR Capital is the largest named holder at 6.6% of shares, with Vanguard and Dimensional both adding recently. Freestone Grove Partners stands out with a Q1 build of nearly 946,000 shares, bringing its stake to 1.3 million — a meaningful position for a less-prominent name worth monitoring. On the insider side, the CEO Vincent Tizzio sold approximately $3.2 million of stock on June 1 at $95.90 — well below the current price — alongside the Independent Chairman's $251,000 sale at $98.69. Both transactions now look like poorly timed disposals given the 19% rally since, and the net 90-day insider balance turned slightly positive after Tizzio's May equity award of 60,662 shares.
The July 28 print is therefore less about whether AXIS can sustain premium growth and more about whether the improved loss ratio narrative holds against what analysts expect to be a tougher comparison period — and how management frames the casualty book's trajectory into year-end.
See the live data behind this article on ORTEX.
Open AXS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
